ABBVIE INC (4AB.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:4AB - US00287Y1091 - Common Stock
187.4 EUR
0 (0%)
Overall 4AB gets a fundamental rating of 5 out of 10. We evaluated 4AB against 86 industry peers in the Biotechnology industry. 4AB has a medium profitability rating, but doesn't score so well on its financial health evaluation. 4AB has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
- In the past year 4AB was profitable.
- 4AB had a positive operating cash flow in the past year.
- In the past 5 years 4AB has always been profitable.
- In the past 5 years 4AB always reported a positive cash flow from operatings.
1.2 Ratios
- 4AB's Return On Assets of 1.75% is fine compared to the rest of the industry. 4AB outperforms 75.90% of its industry peers.
- Looking at the Return On Invested Capital, with a value of 15.64%, 4AB belongs to the top of the industry, outperforming 91.57% of the companies in the same industry.
- Measured over the past 3 years, the Average Return On Invested Capital for 4AB is above the industry average of 11.58%.
- The 3 year average ROIC (13.67%) for 4AB is below the current ROIC(15.64%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.75% | ||
| ROE | N/A | ||
| ROIC | 15.64% |
ROA(3y)5.07%
ROA(5y)5.21%
ROE(3y)80.76%
ROE(5y)70.31%
ROIC(3y)13.67%
ROIC(5y)12.68%
1.3 Margins
- 4AB has a Profit Margin of 3.94%. This is in the better half of the industry: 4AB outperforms 79.52% of its industry peers.
- In the last couple of years the Profit Margin of 4AB has declined.
- 4AB has a better Operating Margin (33.05%) than 89.16% of its industry peers.
- 4AB's Operating Margin has declined in the last couple of years.
- The Gross Margin of 4AB (71.16%) is better than 62.65% of its industry peers.
- In the last couple of years the Gross Margin of 4AB has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.05% | ||
| PM (TTM) | 3.94% | ||
| GM | 71.16% |
OM growth 3Y-5.46%
OM growth 5Y-6.52%
PM growth 3Y-28.3%
PM growth 5Y-20.42%
GM growth 3Y0.39%
GM growth 5Y-1.92%
2. Health
2.1 Basic Checks
- 4AB has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
- 4AB has about the same amout of shares outstanding than it did 1 year ago.
- 4AB has more shares outstanding than it did 5 years ago.
- 4AB has a worse debt/assets ratio than last year.
2.2 Solvency
- 4AB has an Altman-Z score of 2.38. This is not the best score and indicates that 4AB is in the grey zone with still only limited risk for bankruptcy at the moment.
- 4AB has a Altman-Z score of 2.38. This is in the better half of the industry: 4AB outperforms 68.67% of its industry peers.
- The Debt to FCF ratio of 4AB is 3.49, which is a good value as it means it would take 4AB, 3.49 years of fcf income to pay off all of its debts.
- The Debt to FCF ratio of 4AB (3.49) is better than 81.93% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 3.49 | ||
| Altman-Z | 2.38 |
ROIC/WACC1.85
WACC8.43%
2.3 Liquidity
- 4AB has a Current Ratio of 0.72. This is a bad value and indicates that 4AB is not financially healthy enough and could expect problems in meeting its short term obligations.
- 4AB has a Current ratio of 0.72. This is in the lower half of the industry: 4AB underperforms 75.90% of its industry peers.
- A Quick Ratio of 0.60 indicates that 4AB may have some problems paying its short term obligations.
- 4AB's Quick ratio of 0.60 is on the low side compared to the rest of the industry. 4AB is outperformed by 75.90% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.72 | ||
| Quick Ratio | 0.6 |
3. Growth
3.1 Past
- The earnings per share for 4AB have decreased strongly by -12.09% in the last year.
- Measured over the past 5 years, 4AB shows a small growth in Earnings Per Share. The EPS has been growing by 2.51% on average per year.
- Looking at the last year, 4AB shows a small growth in Revenue. The Revenue has grown by 7.40% in the last year.
- Measured over the past years, 4AB shows a quite strong growth in Revenue. The Revenue has been growing by 11.11% on average per year.
EPS 1Y (TTM)-12.09%
EPS 3Y-7.24%
EPS 5Y2.51%
EPS Q2Q%-38%
Revenue 1Y (TTM)7.4%
Revenue growth 3Y0.08%
Revenue growth 5Y11.11%
Sales Q2Q%9.1%
3.2 Future
- 4AB is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.67% yearly.
- Based on estimates for the next years, 4AB will show a small growth in Revenue. The Revenue will grow by 7.50% on average per year.
EPS Next Y7.3%
EPS Next 2Y19.85%
EPS Next 3Y16.87%
EPS Next 5Y13.67%
Revenue Next Year8.74%
Revenue Next 2Y9.15%
Revenue Next 3Y8.74%
Revenue Next 5Y7.5%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 23.05, which indicates a rather expensive current valuation of 4AB.
- 4AB's Price/Earnings ratio is rather cheap when compared to the industry. 4AB is cheaper than 83.13% of the companies in the same industry.
- 4AB's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 27.38.
- With a Price/Forward Earnings ratio of 14.98, 4AB is valued correctly.
- 91.57% of the companies in the same industry are more expensive than 4AB, based on the Price/Forward Earnings ratio.
- Compared to an average S&P500 Price/Forward Earnings ratio of 24.29, 4AB is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 23.05 | ||
| Fwd PE | 14.98 |
4.2 Price Multiples
- 4AB's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. 4AB is cheaper than 79.52% of the companies in the same industry.
- 87.95% of the companies in the same industry are more expensive than 4AB, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 19.55 | ||
| EV/EBITDA | 15.88 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
- 4AB has a very decent profitability rating, which may justify a higher PE ratio.
- A more expensive valuation may be justified as 4AB's earnings are expected to grow with 16.87% in the coming years.
PEG (NY)3.16
PEG (5Y)9.18
EPS Next 2Y19.85%
EPS Next 3Y16.87%
5. Dividend
5.1 Amount
- 4AB has a Yearly Dividend Yield of 3.19%. Purely for dividend investing, there may be better candidates out there.
- 4AB's Dividend Yield is rather good when compared to the industry average which is at 0.75. 4AB pays more dividend than 96.39% of the companies in the same industry.
- Compared to an average S&P500 Dividend Yield of 1.85, 4AB pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.19% |
5.2 History
- The dividend of 4AB is nicely growing with an annual growth rate of 7.72%!
Dividend Growth(5Y)7.72%
Div Incr Years4
Div Non Decr Years4
5.3 Sustainability
- 4AB pays out 489.69% of its income as dividend. This is not a sustainable payout ratio.
- The dividend of 4AB is growing, but earnings are growing more, so the dividend growth is sustainable.
DP489.69%
EPS Next 2Y19.85%
EPS Next 3Y16.87%
FRA:4AB (1/16/2026, 7:00:00 PM)
187.4
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-31 2025-10-31/bmo
Earnings (Next)02-04 2026-02-04/amc
Inst Owners75.04%
Inst Owner ChangeN/A
Ins Owners0.05%
Ins Owner ChangeN/A
Market Cap331.21B
Revenue(TTM)59.64B
Net Income(TTM)2.35B
Analysts78.38
Price Target213.08 (13.7%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.19% |
Yearly Dividend5.38
Dividend Growth(5Y)7.72%
DP489.69%
Div Incr Years4
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1.85%
Min EPS beat(2)0.95%
Max EPS beat(2)2.75%
EPS beat(4)4
Avg EPS beat(4)1.21%
Min EPS beat(4)0.02%
Max EPS beat(4)2.75%
EPS beat(8)7
Avg EPS beat(8)0.95%
EPS beat(12)9
Avg EPS beat(12)0.65%
EPS beat(16)11
Avg EPS beat(16)0.49%
Revenue beat(2)1
Avg Revenue beat(2)-0.08%
Min Revenue beat(2)-0.79%
Max Revenue beat(2)0.63%
Revenue beat(4)2
Avg Revenue beat(4)0.22%
Min Revenue beat(4)-0.79%
Max Revenue beat(4)1.23%
Revenue beat(8)4
Avg Revenue beat(8)0.31%
Revenue beat(12)5
Avg Revenue beat(12)-0.17%
Revenue beat(16)5
Avg Revenue beat(16)-0.74%
PT rev (1m)-0.08%
PT rev (3m)8.41%
EPS NQ rev (1m)-3.35%
EPS NQ rev (3m)-2.56%
EPS NY rev (1m)0.02%
EPS NY rev (3m)-11.46%
Revenue NQ rev (1m)-0.01%
Revenue NQ rev (3m)0.48%
Revenue NY rev (1m)0.01%
Revenue NY rev (3m)0.49%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 23.05 | ||
| Fwd PE | 14.98 | ||
| P/S | 6.45 | ||
| P/FCF | 19.55 | ||
| P/OCF | 18.45 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 15.88 |
EPS(TTM)8.13
EY4.34%
EPS(NY)12.51
Fwd EY6.68%
FCF(TTM)9.59
FCFY5.12%
OCF(TTM)10.16
OCFY5.42%
SpS29.05
BVpS-1.29
TBVpS-45.09
PEG (NY)3.16
PEG (5Y)9.18
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.75% | ||
| ROE | N/A | ||
| ROCE | 20.86% | ||
| ROIC | 15.64% | ||
| ROICexc | 16.59% | ||
| ROICexgc | 572.43% | ||
| OM | 33.05% | ||
| PM (TTM) | 3.94% | ||
| GM | 71.16% | ||
| FCFM | 33% |
ROA(3y)5.07%
ROA(5y)5.21%
ROE(3y)80.76%
ROE(5y)70.31%
ROIC(3y)13.67%
ROIC(5y)12.68%
ROICexc(3y)15.06%
ROICexc(5y)13.91%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)17.54%
ROCE(5y)16.27%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y-1.81%
ROICexc growth 5Y-14.87%
OM growth 3Y-5.46%
OM growth 5Y-6.52%
PM growth 3Y-28.3%
PM growth 5Y-20.42%
GM growth 3Y0.39%
GM growth 5Y-1.92%
F-Score7
Asset Turnover0.45
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 3.49 | ||
| Debt/EBITDA | 2.39 | ||
| Cap/Depr | 14.25% | ||
| Cap/Sales | 1.97% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 74.59% | ||
| Profit Quality | 838.33% | ||
| Current Ratio | 0.72 | ||
| Quick Ratio | 0.6 | ||
| Altman-Z | 2.38 |
F-Score7
WACC8.43%
ROIC/WACC1.85
Cap/Depr(3y)9.59%
Cap/Depr(5y)10.06%
Cap/Sales(3y)1.45%
Cap/Sales(5y)1.5%
Profit Quality(3y)361.43%
Profit Quality(5y)328.91%
High Growth Momentum
Growth
EPS 1Y (TTM)-12.09%
EPS 3Y-7.24%
EPS 5Y2.51%
EPS Q2Q%-38%
EPS Next Y7.3%
EPS Next 2Y19.85%
EPS Next 3Y16.87%
EPS Next 5Y13.67%
Revenue 1Y (TTM)7.4%
Revenue growth 3Y0.08%
Revenue growth 5Y11.11%
Sales Q2Q%9.1%
Revenue Next Year8.74%
Revenue Next 2Y9.15%
Revenue Next 3Y8.74%
Revenue Next 5Y7.5%
EBIT growth 1Y27.38%
EBIT growth 3Y-5.38%
EBIT growth 5Y3.87%
EBIT Next Year9.3%
EBIT Next 3Y15.61%
EBIT Next 5Y10.95%
FCF growth 1Y-20.4%
FCF growth 3Y-6.75%
FCF growth 5Y6.9%
OCF growth 1Y-18.24%
OCF growth 3Y-6.19%
OCF growth 5Y7.14%
ABBVIE INC / 4AB.DE FAQ
What is the ChartMill fundamental rating of ABBVIE INC (4AB.DE) stock?
ChartMill assigns a fundamental rating of 5 / 10 to 4AB.DE.
What is the valuation status for 4AB stock?
ChartMill assigns a valuation rating of 6 / 10 to ABBVIE INC (4AB.DE). This can be considered as Fairly Valued.
How profitable is ABBVIE INC (4AB.DE) stock?
ABBVIE INC (4AB.DE) has a profitability rating of 6 / 10.
Can you provide the financial health for 4AB stock?
The financial health rating of ABBVIE INC (4AB.DE) is 3 / 10.
How sustainable is the dividend of ABBVIE INC (4AB.DE) stock?
The dividend rating of ABBVIE INC (4AB.DE) is 6 / 10 and the dividend payout ratio is 489.69%.